BioCryst Pharmaceuticals | BCRX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Chugai Pharma JPY 258.74B 25.81B 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novavax USD 125.04M 76.09M 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12